Sangamo Therapeutics (SGMO) Earnings Date, Estimates & Call Transcripts $0.56 +0.02 (+4.56%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.56 0.00 (-0.28%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Sangamo Therapeutics Earnings Summary Sangamo Therapeutics posted Q1 2025 earnings on May 12, 2025, reporting an EPS of -$0.14, which missed analysts' consensus estimates of -$0.11 by $0.03. Quarterly revenue was reported to be $6.44 million, below analyst estimates of $7.90 million. With a trailing EPS of -$0.39, Sangamo Therapeutics' earnings are expected to grow next year, from ($0.46) to ($0.26) per share. Upcoming Q2 Earnings DateAug. 7Before Market OpensEstimatedConsensus EPS (May. 12) -$0.11 Actual EPS (May. 12) -$0.14 Missed By -$0.03 Actual Revenue (May. 12) $6.44MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Quarterly Report (10-Q) Slide Deck Press Release (8-K)SGMO Upcoming EarningsSangamo Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 7, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportSlide DeckFull Screen Slide DeckPowered by Get Sangamo Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sangamo Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSGMO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SGMO Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Sangamo Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.04-$0.04-$0.04Q2 20251$0.03$0.03$0.03Q3 20251-$0.08-$0.08-$0.08Q4 20251$0.00$0.00$0.00 FY 2025 4 -$0.09 -$0.09 -$0.09 Q1 20261-$0.06-$0.06-$0.06Q2 20261-$0.06-$0.06-$0.06Q3 20261-$0.07-$0.07-$0.07Q4 20261$0.00$0.00$0.00 Sangamo Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/7/2025(Estimated)-------5/12/2025Q1 2025-$0.11-$0.14 -$0.03-$0.14$7.90M$6.44M3/17/2025Q4 2024-$0.09-$0.11 -$0.02-$0.11$11.70M$7.55M11/12/2024Q3 2024-$0.03$0.04+$0.07$0.04$26.55M$49.41M8/6/2024Q2 2024-$0.16-$0.17 -$0.01-$0.16$11.40M$0.36M5/9/2024Q1 2024-$0.22-$0.27 -$0.05-$0.27$8.51M$0.48M3/13/2024Q4 2023-$0.25-$0.34 -$0.09-$0.34$8.96M$2.04M11/1/2023Q3 2023-$0.33-$0.34 -$0.01-$0.09$10.17M$9.40M8/8/2023Q2 2023-$0.35-$0.37 -$0.02-$0.08$22.33M$6.84M Sangamo Therapeutics Earnings - Frequently Asked Questions When is Sangamo Therapeutics' earnings date? Sangamo Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 7th, 2025 based off last year's report dates. Learn more on SGMO's earnings history. Did Sangamo Therapeutics beat their earnings estimates last quarter? In the previous quarter, Sangamo Therapeutics (NASDAQ:SGMO) missed the analysts' consensus estimate of ($0.11) by $0.03 with a reported earnings per share (EPS) of ($0.14). Learn more on analysts' earnings estimate vs. SGMO's actual earnings. How can I listen to Sangamo Therapeutics' earnings conference call? The conference call for Sangamo Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read Sangamo Therapeutics' conference call transcript? The conference call transcript for Sangamo Therapeutics' latest earnings report can be read online. Read Transcript How much revenue does Sangamo Therapeutics generate each year? Sangamo Therapeutics (NASDAQ:SGMO) has a recorded annual revenue of $57.80 million. How much profit does Sangamo Therapeutics generate each year? Sangamo Therapeutics (NASDAQ:SGMO) has a recorded net income of -$97.94 million. SGMO has generated -$0.39 earnings per share over the last four quarters. What is Sangamo Therapeutics' EPS forecast for next year? Sangamo Therapeutics' earnings are expected to grow from ($0.46) per share to ($0.26) per share in the next year. More Earnings Resources from MarketBeat Related Companies Myriad Genetics Earnings Date Lexicon Pharmaceuticals Earnings Date Emergent Biosolutions Earnings Date Rigel Pharmaceuticals Earnings Date Verastem Earnings Date XOMA Royalty Earnings Date Vanda Pharmaceuticals Earnings Date Crescent Biopharma Earnings Date Codexis Earnings Date Agenus Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Microsoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag? This page (NASDAQ:SGMO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
